dipyridamole + fluorodeoxyuridine

This is a combination of two small molecule drugs, dipyridamole and fluorodeoxyuridine (also known as floxuridine). Dipyridamole is an antiplatelet agent that inhibits the uptake of adenosine into platelets, endothelial cells, and erythrocytes, thereby increasing local concentrations of adenosine which inhibits platelet aggregation. Fluorodeoxyuridine (floxuridine) is an antimetabolite chemotherapeutic agent that acts as a pyrimidine analog; it disrupts DNA synthesis by inhibiting thymidylate synthase after conversion to its active metabolite. The combination has been studied for its potential to enhance the cytotoxicity of fluorodeoxyuridine in cancer therapy—particularly colorectal cancer—by inhibiting thymidine accumulation in tumor cells and reducing efflux of FUDR from these cells. Clinical studies have shown increased cytotoxicity in vitro but only modest clinical responses in metastatic colon cancer patients[1][2][4].

Other names

dipyridamole and fluorodeoxyuridineDP + FUDR